Download PDF
Thromb Haemost 1999; 82(02): 576-584
DOI: 10.1055/s-0037-1615883
Research Article
Schattauer GmbH

Structure and Function of von Willebrand Factor

Zaverio M. Ruggeri
1   Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Introduction

The reader will find here a concise summary of established notions on the structure and function of von Willebrand factor (vWF), followed by a brief discussion of selected recent advances that illustrate how this molecule supports platelet function in hemostasis and thrombosis. A comprehensive review of the topic is beyond the scope of this chapter and may be found elsewhere.1-3

 

  • References

  • 1 Ruggeri ZM, Saldivar E. Platelets, hemostasis and thrombosis. Ruggeri ZM. ed. Von Willebrand Factor and the Mechanisms of Platelet Function. Berlin: Springer; 1998: 1-32.
    Google Scholar
  • 2 Ruggeri ZM. Structure and biosynthesis of von Willebrand factor. In: Ruggeri ZM. ed. Von Willebrand Factor and the Mechanisms of Platelet Function. Berlin: Springer; 1998: 33-77.
    Google Scholar
  • 3 Ruggeri ZM, Savage B. Biological functions of von Willebrand factor. In: Ruggeri ZM. ed. Von Willebrand Factor and the Mechanisms of Platelet Function. Berlin: Springer; 1998: 79-109.
    Google Scholar
  • 4 Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (Factor VIII deficiency) and von Willebrand’s disease. With observations on combined deficiencies of antihemophilic factor and proaccelerin (Factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 1971; 50: 244-254.
    CrossrefPubMedGoogle Scholar
  • 5 van Mourik JA, Bouma BN, La Bruyere WT, de Graaf S, Mochtar IA. Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res 1974; 4: 155-164.
    CrossrefPubMedGoogle Scholar
  • 6 Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-1325.
    CrossrefPubMedGoogle Scholar
  • 7 Hoyer LW, Shainoff JR. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood 1980; 55: 1056-1059.
    PubMedGoogle Scholar
  • 8 Perret BA, Furlan M, Beck EA. Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers. Biochim Biophys Acta 1979; 578: 164-174.
    CrossrefPubMedGoogle Scholar
  • 9 Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-1143.
    PubMedGoogle Scholar
  • 10 Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 774-782.
    CrossrefPubMedGoogle Scholar
  • 11 Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-3184.
    CrossrefPubMedGoogle Scholar
  • 12 Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Clin Invest 1985; 76: 1491-1500.
    CrossrefPubMedGoogle Scholar
  • 13 Fowler WE, Fretto LJ. Electron microscopy of von Willebrand factor. In: Zimmerman TS, Ruggeri ZM. eds. Coagulation and Bleeding Disorders. The Role of Factor VIII and von Willebrand Factor. New York: Marcel Dekker, Inc; 1989: 181-193.
    Google Scholar
  • 14 Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (Types IIC, IID and IIE). J Clin Invest 1986; 77: 947-951.
    CrossrefPubMedGoogle Scholar
  • 15 Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 6306-6310.
    CrossrefPubMedGoogle Scholar
  • 16 Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46: 185-190.
    CrossrefPubMedGoogle Scholar
  • 17 Lopez-Fernandez MF, Ginsberg MH, Ruggeri ZM, Batlle J, Zimmerman TS. Multimeric structure of platelet factor VIII/von Willebrand factor. The presence of larger multimers and their reassociation with thrombin-stimulated platelets. Blood 1982; 60: 1132-1138.
    PubMedGoogle Scholar
  • 18 Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azacar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
    CrossrefPubMedGoogle Scholar
  • 19 Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
    PubMedGoogle Scholar
  • 20 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
    PubMedGoogle Scholar
  • 21 Siediecki CA, Lestini BJ, Kottke-Marchant K, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
    PubMedGoogle Scholar
  • 22 Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-19527.
    PubMedGoogle Scholar
  • 23 Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GAP, Latt SA, Orkin SH. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228: 1401-1406.
    CrossrefPubMedGoogle Scholar
  • 24 Mancuso DJ, Tuley EA, Westfield LA, Lester-Mancuso TL, Le Beau MM, Sorace JM, Sadler JE. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991; 30: 253-269.
    CrossrefPubMedGoogle Scholar
  • 25 Jahroudi N, Lynch DC. Endothelial-cell-specific regulation of von Willebrand factor gene expression. Mol Cell Biol 1994; 14: 999-1008.
    CrossrefPubMedGoogle Scholar
  • 26 Ferreira V, Assouline Z, Schwachtgen JL, Bahnak BR, Meyer D, Kerbiriou-Nabias D. The role of the 5’-flanking region in the cell-specific transcription of the human von Willebrand factor gene. Biochem J 1993; 293: 641-648.
    CrossrefPubMedGoogle Scholar
  • 27 Aird WC, Jahroudi N, Weiler-Guettler H, Rayburn HB, Rosenberg RD. Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci USA 1995; 92: 4567-4571.
    CrossrefPubMedGoogle Scholar
  • 28 Wu QY, Drout L, Carrier JL, Rothschild C, Berard M, Rouault C, Caen JP, Meyer D. Differential distribution of von Willebrand factor in endothelial cells. Comparison between normal pigs and pigs with von Willebrand disease. Arteriosclerosis 1987; 7: 47-54.
    CrossrefPubMedGoogle Scholar
  • 29 Bahnak BR, Wu Q-Y, Coulombel L, Assouline Z, Kerbiriou-Nabias D, Pietu G, Drouet L, Caen JP, Meyer D. Expression of von Willebrand factor in porcine vessels: heterogeneity at the level of von Willebrand factor mRNA. J Cell Physiol 1989; 138: 305-310.
    CrossrefPubMedGoogle Scholar
  • 30 Bonthron DT, Handin RI, Kaufman RJ, Wasley LC, Orr EC, Mitsock LM, Ewenstein B, Loscalzo J, Ginsburg D, Orkin SH. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature 1986; 324: 270-273.
    CrossrefPubMedGoogle Scholar
  • 31 Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J 1986; 5: 1839-1847.
    PubMedGoogle Scholar
  • 32 Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA 1987; 84: 1955-1959.
    CrossrefPubMedGoogle Scholar
  • 33 Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel–Palade bodies. Blood 1994; 83: 3536-3544.
    PubMedGoogle Scholar
  • 34 Fay PJ, Kawai Y, Wagner DD, Ginsburg D, Bonthron D, Ohlsson-Wilhelm BM, Chavin SI, Abraham GN, Handin RI, Orkin SH, Montgomery RR, Marder VJ. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science 1986; 232: 995-998.
    CrossrefPubMedGoogle Scholar
  • 35 Montgomery RR, Zimmerman TS. von Willebrand’s disease antigen II: a new plasma and platelet antigen deficient in severe von Willebrand’s disease. J Clin Invest 1978; 61: 1498-1507.
    CrossrefPubMedGoogle Scholar
  • 36 Shelton-Inloes BB, Titani K, Sadler JE. cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms. Biochemistry 1986; 25: 3164-3171.
    CrossrefPubMedGoogle Scholar
  • 37 Colombatti A, Bonaldo P. The superfamily of proteins with von Willebrand factor type A-like domains: one theme common to components of extracellular matrix, hemostasis, cellular adhesion, and defense mechanisms. Blood 1991; 77: 2305-2315.
    PubMedGoogle Scholar
  • 38 Hunt LT, Barker WC. von Willebrand Factor shares a distinctive cystein-rich domain with thrombospondin and procollagen. Biochem Biophys Res Commun 1987; 144: 876-882.
    CrossrefPubMedGoogle Scholar
  • 39 Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins, and platelets. Thromb Haemost 1988; 59: 1-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell 1992; 69: 11-25.
    CrossrefPubMedGoogle Scholar
  • 41 Wagner DD, Lawrence SO, Ohlsson-Wilhelm BM, Fay PJ, Marder VJ. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood 1987; 69: 27-32.
    PubMedGoogle Scholar
  • 42 Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol 1991; 113: 195-205.
    CrossrefPubMedGoogle Scholar
  • 43 Schneppenheim R, Brassard J, Krey S, Budde U, Kunicki TJ, Holmberg L, Ware J, Ruggeri ZM. Defective dimerization of von Willebrand factor subunits due to a Cys to Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci USA 1996; 93: 3581-3586.
    CrossrefPubMedGoogle Scholar
  • 44 Voorberg J, Fontijn R, van Mourik JA, Pannekoek H. Domains involved in multimer assembly of von Willebrand factor (vWF): multimerization is independent of dimerization. EMBO J 1990; 9: 797-803.
    PubMedGoogle Scholar
  • 45 Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci USA 1992; 89: 3531-3535.
    CrossrefPubMedGoogle Scholar
  • 46 Kinoshita S, Harrison J, Lazerson J, Abildgaard CF. A new variant of dominant type II von Willebrand’s disease with aberrant multimeric pattern of factor VIII-related antigen (type IID). Blood 1984; 63: 1369-1371.
    PubMedGoogle Scholar
  • 47 Loesberg C, Gonsalves MD, Zandbergen J, Willems C, Van Aken WG, Stel HV, van Mourik JA, DeGroot PG. The effect of calcium on the secretion of factor VIII-related antigen by cultured human endothelial cells. Biochim Biophys Acta 1983; 763: 160-168.
    CrossrefPubMedGoogle Scholar
  • 48 Wagner DD. Storage and secretion of von Willebrand factor. In: Zimmerman TS, Ruggeri ZM. eds. Coagulation and Bleeding Disorders. The Role of Factor VIII and von Willebrand Factor. New York: Marcel Dekker, Inc; 1989: 161-180.
    Google Scholar
  • 49 Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-246.
    CrossrefPubMedGoogle Scholar
  • 50 v.d. Kwast TH, Stel HV, Cristen E, Bertina RM, Veerman ECI. Localization of factor VIII-procoagulant antigen: an immunohistological survey of the human body using monoclonal antibodies. Blood 1986; 67: 222-227.
    PubMedGoogle Scholar
  • 51 Takeuchi M, Nagura H, Kaneda T. DDAVP and epinephrine-induced changes in the localization of von Willebrand factor antigen in endothelial cells of human oral mucosa. Blood 1988; 72: 850-854.
    PubMedGoogle Scholar
  • 52 Hop C, Fontijn R, VanMourik JA, Pannekoek H. Polarity of constitutive and regulated von Willebrand factor secretion by transfected MDCK-II cells. Exp Cell Res 1997; 230: 352-361.
    CrossrefPubMedGoogle Scholar
  • 53 Nachman RL, Levine R, Jaffe EA. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest 1977; 60: 914-921.
    CrossrefPubMedGoogle Scholar
  • 54 Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76: 1102-1106.
    CrossrefPubMedGoogle Scholar
  • 55 Bowie EJ, Solberg Jr LA, Fass DN, Johnson CM, Knutson GJ, Stewart ML, Zoecklein LJ. Transplantation of normal bone marrow into a pig with severe von Willebrand’s disease. J Clin Invest 1986; 78: 26-30.
    CrossrefPubMedGoogle Scholar
  • 56 Koutts J, Walsh PN, Plow EF, Fenton JW, Bouma BN, Zimmerman TS. Active release of human platelet Factor VIII-related antigen by adenosine diphosphate, collagen and thrombin. J Clin Invest 1978; 62: 1255-1263.
    CrossrefPubMedGoogle Scholar
  • 57 Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites within human von Willebrand factor for monomeric type III collagen. Biochemistry 1986; 25: 8357-8361.
    CrossrefPubMedGoogle Scholar
  • 58 Pareti FI, Fujimura Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM. Isolation and characterization of a collagen binding domain in human von Willebrand factor. J Biol Chem 1986; 261: 15310-15315.
    PubMedGoogle Scholar
  • 59 Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem 1987; 262: 13835-13841.
    PubMedGoogle Scholar
  • 60 Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glyco-protein Ib heparin, and collagen, and characterization of its three distinct functional sites. J Biol Chem 1989; 264: 17361-17367.
    PubMedGoogle Scholar
  • 61 Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor (vWF) with collagen. J Biol Chem 1995; 270: 10822-10827.
    CrossrefPubMedGoogle Scholar
  • 62 Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermylen J. von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem J 1997; 324: 185-191.
    CrossrefPubMedGoogle Scholar
  • 63 Yamamoto H, Vermylen J, Hoylaerts MF. Exposure of von Willebrand factor to shear forces stimulates A1 domain mediated interaction with collagen. Thromb Haemost 1997; 78: 642-643.
    PubMedGoogle Scholar
  • 63a Mazzucato M, Spessotto P, Masotti A, De Appollonia L, Cozzi MR, Yoshioka A, Perris R, Colombatti A, De Marco L. Identification of domains responsible for von Willebrand factor type VI collagen interaction mediating platelet adhesion under high flow. J Biol Chem 1999; 274: 3033-3041.
    CrossrefPubMedGoogle Scholar
  • 64 Fujimura Y, Titani K, Holland LZ, Roberts JR, Kostel P, Ruggeri ZM, Zimmerman TS. A heparin-binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. J Biol Chem 1987; 262: 1734-1739.
    PubMedGoogle Scholar
  • 65 Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem 1992; 267: 8857-8862.
    PubMedGoogle Scholar
  • 66 Fretto LJ, Fowler WE, McCaslin DR, Erickson HP, McKee PA. Substructure of human von Willebrand factor. Proteolysis by V8 and characterization of two functional domains. J Biol Chem 1986; 261: 15679-15689.
    PubMedGoogle Scholar
  • 67 Fujimura Y, Titani K, Holland LZ, Russell SR, Roberts JR, Elder JH, Ruggeri ZM, Zimmerman TS. von Willebrand factor. A reduced and alkylated 52/48 kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986; 261: 381-385.
    PubMedGoogle Scholar
  • 68 Mohri H, Fujimura Y, Shima M, Yoshioka A, Houghten RA, Ruggeri ZM, Zimmerman TS. Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem 1988; 263: 17901-17904.
    PubMedGoogle Scholar
  • 69 Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 1991; 266: 8149-8155.
    PubMedGoogle Scholar
  • 70 Berndt MC, Ward CM, Booth WJ, Castaldi PA, Mazurov AV, Andrews RK. Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanisms of modulation of von Willebrand factor by ristocetin and botrocetin. Biochemistry 1992; 31: 11144-11151.
    CrossrefPubMedGoogle Scholar
  • 71 Knott HM, Berndt MC, Kralicek AV, O’Donoghue SI, King GF. Determination of the solution structure of a platelet-adhesion peptide of von Willebrand factor. Biochemistry 1992; 31: 11152-11158.
    CrossrefPubMedGoogle Scholar
  • 72 Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1995; 270: 13406-13414.
    CrossrefPubMedGoogle Scholar
  • 73 Celikel R, Varughese KI, Madhusudan A, Yoshioka A, Ware J, Ruggeri ZM. Crystal structure of von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nat Struct Biol 1998; 5: 189-194.
    CrossrefPubMedGoogle Scholar
  • 74 Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem 1998; 273: 10396-10401.
    CrossrefPubMedGoogle Scholar
  • 75 Huizinga EG, van der Plas RM, Kroon J, Sixma JJ, Gros P. Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding. Structure 1997; 5: 1147-1156.
    CrossrefPubMedGoogle Scholar
  • 76 Bienkowska J, Cruz MA, Handin RI, Liddington RC. The von Willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif. J Biol Chem 1997; 272: 25162-25167.
    CrossrefPubMedGoogle Scholar
  • 77 Lee J-O, Rieu P, Arnaout MA, Liddington R. Crystal structure of the A domain from the α subunit of integrin CR3 (CD11b/CD18). Cell 1995; 80: 631-638.
    CrossrefPubMedGoogle Scholar
  • 78 Qu A, Leahy DJ. Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, αLβ2) integrin. Proc Natl Acad Sci USA 1995; 92: 10277-10281.
    CrossrefPubMedGoogle Scholar
  • 79 Emsley J, King SL, Bergelson JM, Liddington TC. Crystal structure of the I domain from integrin α 2β1. J Biol Chem 1997; 272: 28512-28517.
    CrossrefPubMedGoogle Scholar
  • 80 Kamata T, Puzon W, Takada Y. Identification of putative ligand binding sites within I domain of integrin alpha 2 beta 1 (VLA-2, CD49b/CD29). J Biol Chem 1994; 269: 9659-9663.
    PubMedGoogle Scholar
  • 81 Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-33.
    CrossrefPubMedGoogle Scholar
  • 82 Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-497.
    CrossrefPubMedGoogle Scholar
  • 83 Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549-554.
    CrossrefPubMedGoogle Scholar
  • 84 Plow EF, Srouji AH, Meyer D, Marguerie G, Ginsberg MH. Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem 1984; 259: 5385-5391.
    PubMedGoogle Scholar
  • 85 Berliner S, Niiya K, Roberts JR, Houghten RA, Ruggeri ZM. Generation and characterization of peptide-specific antibodies that inhibit von Willebrand factor binding to GP IIb-IIIa without interacting with other adhesive molecules: selectivity is conferred by Pro 1743 and other amino acid residues adjacent to the sequence Arg1744-Gly1745-Asp1746. J Biol Chem 1988; 263: 7500-7505.
    PubMedGoogle Scholar
  • 86 Beacham DA, Wise RJ, Turci SM, Handin RI. Selective inactivation of the Arg-Gly-Asp-Ser (RGDS) binding site in von Willebrand factor by site-directed Mutagenesis. J Biol Chem 1992; 267: 3409-3415.
    PubMedGoogle Scholar
  • 87 Dejana E, Lampugnani MG, Giorgi M, Gaboli M, Federici AB, Ruggeri ZM. von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly-Asp-dependent mechanism. J Cell Biol 1989; 109: 367-375.
    CrossrefPubMedGoogle Scholar
  • 88 Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 8443-8446.
    PubMedGoogle Scholar
  • 89 Bahou WF, Ginsburg D, Sikkink R, Litwiller R, Fass DN. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a non-adecapeptide at the amino terminus of the mature vWF polypeptide. J Clin Invest 1989; 84: 56-61.
    CrossrefPubMedGoogle Scholar
  • 90 Ginsburg D, Bockenstedt PL, Allen EA, Fox DA, Foster PA, Ruggeri ZM, Zimmerman TS, Montgomery RR, Bahou WF, Johnson TA, Yang AY. Fine mapping of monoclonal antibody epitopes on human von Willebrand factor using a recombinant peptide library. Thromb Haemost 1992; 67: 166-171.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 91 Tuley EA, Gaucher C, Jorieux S, Worrall NK, Sadler JE, Mazurier C. Expression of von Willebrand factor “Normandy:” an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci USA 1991; 88: 6377-6381.
    CrossrefPubMedGoogle Scholar
  • 92 Gaucher C, Mercier B, Jorieux S, Oufkir D, Mazurier C. Identification of two point mutations in the von Willebrand factor gene of three families with the “Normandy” variant of von Willebrand disease. Br J Haematol 1991; 78: 506-514.
    CrossrefPubMedGoogle Scholar
  • 93 Cacheris PM, Nichols WC, Ginsburg D. Molecular characterization of a unique von Willebrand disease variant. J Biol Chem 1991; 266: 13499-13502.
    PubMedGoogle Scholar
  • 94 Kroner PA, Friedman KD, Fahst SA, Scott JP, Montgomery RR. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem 1991; 266: 19146-19149.
    PubMedGoogle Scholar
  • 95 Gu J, Jorieux S, Lavergne JM, Ruan C, Mazurier C, Meyer D. A patient with type 2N von Willebrand disease is heterozygous for a new mutation: Gly22Glu. Demonstration of a defective expression of the second allele by the use of monoclonal antibodies. Blood 1997; 89: 3263-3269.
    PubMedGoogle Scholar
  • 96 Roberts DD, Williams SB, Gralnick HR, Ginsburg V. von Willebrand factor binds specifically to sulfated glycolipids. J Biol Chem 1986; 261: 3306-3309.
    PubMedGoogle Scholar
  • 97 Christophe O, Obert B, Meyer D, Girma J-P. The binding domain of von Willebrand factor to sulfatides is distinct from those interacting with glycoprotein Ib heparin, and collagen and resides between amino acid residues Leu 512 and Lys 673. Blood 1991; 78: 2310-2317.
    PubMedGoogle Scholar
  • 98 Ribes JA, Francis CW. Multimer size dependence of von Willebrand factor binding to crosslinked or noncrosslinked fibrin. Blood 1990; 75: 1460-1465.
    PubMedGoogle Scholar
  • 99 Hada M, Kaminski M, Bockenstedt P, McDonagh J. Covalent crosslinking of von Willebrand Factor to fibrin. Blood 1986; 68: 95-101.
    PubMedGoogle Scholar
  • 100 Tangelder GJ, Slaaf DW, Arts T, Reneman RS. Wall shear rate in arterioles in vivo: least estimates from platelet velocity profiles. Am J Physiol 1988; 254: H1059-H1064
    PubMedGoogle Scholar
  • 101 Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297.
    CrossrefPubMedGoogle Scholar
  • 102 Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666.
    CrossrefPubMedGoogle Scholar
  • 103 Back CH, Radbill JR, Crawford DW. Analysis of pulsatile viscous blood flow through diseased coronary arteries of man. J Biomech (Tokyo) 1977; 10: 339-353.
    CrossrefPubMedGoogle Scholar
  • 104 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-1240.
    CrossrefPubMedGoogle Scholar
  • 105 Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell 1991; 65: 359-362.
    CrossrefPubMedGoogle Scholar
  • 106 Polanowska-Grabowska R, Geanacopoulos M, Gear ARL. Platelet adhesion to collagen via the α2β1 integrin under flow conditions causes rapid tyrosine phosphorylation of pp125FAK . Biochem J 1993; 296: 543-547.
    CrossrefPubMedGoogle Scholar
  • 107 Keely PJ, Parise LV. The α2β1 integrin is a necessary co-receptor for collagen-induced activation of Syk and subsequent phosphorylation of phospholipase Cy2 in platelets. J Biol Chem 1996; 271: 26668-26676.
    CrossrefPubMedGoogle Scholar
  • 108 Nieuwenhuis HK, Akkerman JWN, Houdijk WPM, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985; 318: 470-472.
    CrossrefPubMedGoogle Scholar
  • 109 Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998; 101: 479-486.
    CrossrefPubMedGoogle Scholar
  • 110 Weiss HJ. Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med 1975; 293: 531-541.
    CrossrefPubMedGoogle Scholar
  • 111 Weiss HJ. Platelet physiology and abnormalities of platelet function (second of two parts). N Engl J Med 1975; 293: 580-588.
    CrossrefPubMedGoogle Scholar
  • 112 Sixma JJ, Wester J. The hemostatic plug. Semin Hematol 1977; 14: 265-299.
    PubMedGoogle Scholar
  • 113 Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996; 88: 1525-1541.
    PubMedGoogle Scholar
  • 114 Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood. In press.
    PubMedGoogle Scholar